Gain Therapeutics (GANX) Other financing activities (2020 - 2026)

Gain Therapeutics has reported Other financing activities for 5 years, with the latest figure at $2063.0 in Q1 2026.

• On a quarterly basis, Other financing activities changed N/A year-over-year to $2063.0 in Q1 2026; TTM through Jun 2026 was $1.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $3.2 million, up 2728.25% from the prior year.
• Other financing activities was $2063.0 for Q1 2026 at Gain Therapeutics, down from $1.3 million in the prior quarter.
• The five-year high for Other financing activities was $1.3 million in Q4 2025, with the low at -$1.0 in Q4 2024.
• Average Other financing activities over 3 years is $208266.1, with a median of $13575.0 recorded in 2024.
• The largest YoY upside for Other financing activities was 130000100.0% in 2025 against a maximum downside of 4199900.0% in 2025.
• Over 3 years, Other financing activities stood at -$1.0 in 2024, then surged by 130000100.0% to $1.3 million in 2025, then slumped by 99.84% to $2063.0 in 2026.
• The last three Other financing activities figures came in at $2063.0 (Q1 2026), $1.3 million (Q4 2025), and $42000.0 (Q3 2025), per Business Quant data.